Pages that link to "Q79975719"
Jump to navigation
Jump to search
The following pages link to Presymptomatic neuromuscular disorders disclosed following statin treatment (Q79975719):
Displaying 14 items.
- Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism (Q24603957) (← links)
- Pharmacogenomic insights into treatment and management of statin-induced myopathy (Q33600104) (← links)
- Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase (Q34579854) (← links)
- A neuromuscular approach to statin-related myotoxicity. (Q37124768) (← links)
- Statins may aggravate myasthenia gravis (Q37162015) (← links)
- Is a statin as part of a polypill the answer? (Q37350166) (← links)
- A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs (Q38113494) (← links)
- Metabolic myopathies discovered during investigations of statin myopathy. (Q46671140) (← links)
- Effect of atorvastatin on energy expenditure and skeletal muscle oxidative metabolism at rest and during exercise (Q80442031) (← links)
- Two cases of statin-induced rhabdomyolysis associated with mononeuropathy (Q84042613) (← links)
- Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence (Q89022021) (← links)
- Development of AD-Like Pathology in Skeletal Muscle (Q90451860) (← links)
- Clinical features related to statin-associated muscle symptoms (Q90482667) (← links)
- Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components (Q92156926) (← links)